Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Curetis AG. (11/24/14). "Press Release: Curetis Closes EUR 14.5 Million Extension of Series B Financing". Holzgerlingen.

Organisations Organisation Curetis AG
  Group Curetis (Group)
  Organisation 2 LSP HEF (Life Sciences Partners Health Economics Fund)
  Group Life Sciences Partners (LSP)
Products Product Unyvero molecular diagnostics platform
  Product 2 venture capital
Index terms Index term Curetis–SEVERAL: investment, 201411 financing round Series B extension €14.5m new investors Qiagen + LSP-HEF + all existing investors
  Index term 2 Curetis–Qiagen: investment, 201411 financing round Series B extension totalling €14.5m incl €7m from two new investors Qiagen + LSP-HEF
Persons Person Dekeyser, Rudy (Life Sciences Partners 201403 Managing Partner LSP HEF)
  Person 2 Potgeter, Martin (Qiagen 201411 VP Business Development)

- Curetis wins new investors QIAGEN and LSP-HEF, committing EUR 7 million

- Curetis well financed into 2017

Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013. All existing investors – aeris Capital, BioMed Invest, CD Venture, Forbion Capital, HBM Partners, LSP - Life Sciences Partners, Roche Venture Fund, management, a trusteepool of Curetis employees and private angel investors - participated in the extension financing, investing EUR 7.5 million on a pro rata basis.

QIAGEN and LSP Health Economics Fund (LSP-HEF) are joining as new investors, committing a total of EUR 7 million. The financing brings the total amount of equity raised by Curetis AG to over EUR 63.5 million. In addition, Rudy Dekeyser of LSP-HEF will join Curetis´ Supervisory Board, while Hans-Guenter Hohmann will step down after being a Board member for the past six years. Dr. Martin Potgeter, Vice President Business Development of QIAGEN, will take an observer seat on the board as second representative of a corporate investor alongside Simon Meier of Roche Venture Fund and Dr. Karsten Fischer of BioMed Invest.

The financing is supported by the achievement of key milestones, e.g. several CE/IVD-marked products, an ongoing FDA clearance trial and a growing commercial distribution network across Europe. The European market introduction of both the Unyvero P50 Pneumonia and i60 Implant and Tissue Infection applications, allowing a faster and better diagnosis of life-threatening infectious diseases, has shown increasing traction. In addition, the company is in talks with several parties on granting future U.S. commercialization rights and further expanding the commercialization into Asia and other global markets.

"With our unique focus on equity stories that have products with an immediate, strong and clear health economics impact, the investment in Curetis comes quite naturally," said Rudy Dekeyser, Managing Partner of LSP-HEF. "The Unyvero solution provides not only better medical outcomes based on more rational antibiotic therapy decisions, but at the same time offers hospitals and healthcare systems substantial savings under ever tighter DRGs. As an example, Unyvero improves the number of adequately treated pneumonia patients and reduces the average length of stay in intensive care units.”

“We are excited to see two new investors joining and further strengthening our syndicate of top-tier private equity funds," said Dr. Oliver Schacht, CEO of Curetis. "This provides further evidence of our growth story being an attractive investment case. With the current cash on hand, we are now financed well into 2017. The funds will be used to continue our commercial roll-out in Europe, the FDA trial and to prepare our company for attractive future exit opportunities such as strategic partnerships, M&A or an IPO."

Further details on the Unyvero platform are available at the new Unyvero product website In addition to details of the Unyvero range of products, the site offers downloads of all scientific and clinical publications using Unyvero. Please visit: and


CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.


About the Unyvero System

The CE-marked Unyvero System is a versatile hardware platform for the detection of a broad panel of bacteria, fungi and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result. It is marketed in Europe, Russia, the Middle East and various other non-European countries. In the U.S., Curetis is running a prospective multi-center clinical trial aimed at achieving FDA clearance registered under .

The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure.

Thereby, clinically relevant information is available within about four to five hours to support an informed therapy decision as early as possible.

The first CE-marked Unyvero Cartridge, Unyvero P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. The second CE-marked application, the Unyvero i60 ITI cartridge for implant & tissue infections, is also commercially available in Europe and is currently being evaluated in the prospective multi-center EPJIC study .

Cartridges for additional indications are in various stages of development and preparation.

For further information, please visit

About Curetis AG

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised total funds of over EUR 63.5 million (US$ 80 million). The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering more than 20 countries.

For further information, please visit


Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10 -

Media Inquiries

Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Curetis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top